



## Curriculum Vitae

Personal information **Jean-Michel Dogné**

### Work experience

---

1. Employer: University of Liège
  - Start date: 071996
  - End date: 112000
  - Position: PhD Student in pharmaceutical sciences
  - Activities: PH.D. Thesis Drug design and development
  - Country: Belgium
2. Employer: University of Liège
  - Start date: 122000
  - End date: 092005
  - Position: PhD, Assistant (Professor)
  - Activities: Drug design, drug development
  - Country: Belgium
3. Employer: Federal Agency for Medicines and Health Products
  - Start date: 012006
  - End date:
  - Position: Expert in pharmacovigilance
  - Activities: Pharmacovigilance, Drug safety
  - Country: Belgium
4. Employer: Federal Agency for Medicines and Health Products
  - Start date: 052006
  - End date: 072012
  - Position: Belgian delegate at the PhVWP of the EMA
  - Activities: Pharmacovigilance, Drug safety
  - Country: Belgium
5. Employer: Federal Agency for Medicines and Health Products
  - Start date: 072012
  - End date:
  - Position: Belgian member of the PRAC of the EMA
  - Activities: Pharmacovigilance, Drug safety
  - Country: Belgium
6. Employer: University of Namur
  - Start date: 092005
  - End date:
  - Position: Full Professor
  - Activities: Regulatory medicines, Drug development, Pharmacology (non clinical & clinical), Thrombosis & Hemostasis research, Nanotoxicology, Pharmacovigilance, Drug safety, Vaccine safety
  - Country: Belgium
7. Employer: WHO
  - Start date: 052020
  - End date:
  - Position: Member of the GACVS (Global Advisory Committee on Vaccine Safety)
  - Activities: Vaccine safety
  - Country: Switzerland

### Education and training

---

1. Subject: University of Liège
  - Start date: 091991
  - End date: 071996
  - Qualification: Pharm.D.
  - Organisation:
  - Country: Belgium
2. Subject: University of Liège
  - Start date: 091996
  - End date: 112000
  - Qualification: Ph.D in pharmaceutical sciences
  - Organisation:
  - Country: Belgium

### Additional information

---

## Publications

- 1: Favresse J, Gillot C, Cabo J, David C, Dogné JM, Douxfils J. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1 and JN.1 six months after the BNT162b2 bivalent booster. *Int J Infect Dis.* 2024 Apr 5;107028. doi: 10.1016/j.ijid.2024.107028. Epub ahead of print. PMID: 38583825.
- 2: Vassart J, Didembourg M, Morimont L, Brisbois C, Jamart L, Lebreton A, Mullier F, Donis N, Favresse J, Dogné JM, Douxfils J. Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure? *Thromb Res.* 2024 Apr;236:236-239. doi: 10.1016/j.thromres.2024.03.001. Epub 2024 Mar 7. PMID: 38484630.
- 3: Favresse J, Gillot C, Closset M, Cabo J, Wauthier L, David C, Elsen M, Dogné JM, Douxfils J. Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster. *J Med Virol.* 2024 Jan;96(1):e29365. doi: 10.1002/jmv.29365. PMID: 38185981.
- 4: Douxfils J, Beaudart C, Dogné JM. Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant. *Lancet.* 2023 Nov 4;402(10413):1623-1625. doi: 10.1016/S0140-6736(23)01634-3. Epub 2023 Oct 18. PMID: 37865107.
- 5: Micallef B, Dogné JM, Sultana J, Straus SMJM, Nisticò R, Serracino-Inglott A, Borg JJ. An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance. *Drug Saf.* 2023 Nov;46(11):1089-1103. doi: 10.1007/s40264-023-01346-9. Epub 2023 Sep 14. PMID: 37707778.
- 6: Bizimungu C, Sabbe M, Wuillaume F, Hamdani J, Koch P, Dogné JM. Challenges in Assessing COVID-19 Vaccines Safety Signals-The Case of ChAdOx1 nCoV-19 Vaccine and Corneal Graft Rejection. *Vaccines (Basel).* 2023 May 6;11(5):954. doi: 10.3390/vaccines11050954. PMID: 37243058; PMCID: PMC10221427.
- 7: Cuyper L, Keyaerts E, Hong SL, Gorissen S, Menezes SM, Starck M, Van Elslande J, Weemaes M, Wawina-Bokalanga T, Marti-Carreras J, Vanmechelen B, Van Holm B, Bloemen M, Dogne JM, Dufrasne F, Durkin K, Ruelle J, De Mendonca R, Wollants E, Vermeersch P; COVID-19 Genomics Belgium Consortium; Boulouffe C, Djena A, Broucke C, Catry B, Lagrou K, Van Ranst M, Neyts J, Baele G, Maes P, André E, Dellicour S, Van Weyenbergh J. Immunovirological and environmental screening reveals actionable risk factors for fatal COVID-19 during post-vaccination nursing home outbreaks. *Nat Aging.* 2023 Jun;3(6):722-733. doi: 10.1038/s43587-023-00421-1. Epub 2023 May 22. PMID: 37217661; PMCID: PMC10275758.
- 8: Simon G, Favresse J, Gillot C, Closset M, Catry É, Dogné JM, Douxfils J, Wieërs G, Bayart JL. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration. *Clin Chem Lab Med.* 2023 Apr 21;61(10):1875-1885. doi: 10.1515/cclm-2022-1258. PMID: 37078220.
- 9: Gillot C, Bayart JL, Closset M, Cabo J, Maloteau V, Dogné JM, Douxfils J, Favresse J. Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing. *Clin Chem Lab Med.* 2023 Apr 3;61(9):1670-1675. doi: 10.1515/cclm-2023-0134. PMID: 36999398.
- 10: Beyens M, Toscano A, Van Damme P, Dogné JM, Ebo DG, Sabato V. Perceived high risk of COVID-19 vaccination: The revealing power of placebo. *J Allergy Clin Immunol Pract.* 2023 Jun;11(6):1954-1956. doi: 10.1016/j.jaip.2023.03.031. Epub 2023 Mar 24. PMID: 36965707; PMCID: PMC10036145.
- 11: Bayart JL, Gillot C, Dogné JM, Roussel G, Verbelen V, Favresse J, Douxfils J. Clinical performance evaluation of the Fluorecare® SARS-CoV-2 & Influenza A/B & RSV rapid antigen combo test in symptomatic individuals. *J Clin Virol.* 2023 Apr;161:105419. doi: 10.1016/j.jcv.2023.105419. Epub 2023 Feb 28. PMID: 36905798; PMCID: PMC9970915.
- 12: Musuamba FT, Cheung SYA, Colin P, Davies EH, Barret JS, Pappalardo F, Chappell M, Dogne JM, Ceci A, Della Pasqua O, Rusten IS. Moving Toward a Question-Centric Approach for Regulatory Decision Making in the Context of Drug Assessment. *Clin Pharmacol Ther.* 2023 Jul;114(1):41-50. doi: 10.1002/cpt.2856. Epub 2023 Mar 3. PMID: 36708100.
- 13: Gillot C, Favresse J, Maloteau V, Mathieux V, Dogné JM, Mullier F, Douxfils J. Resistance towards ChadOx1 nCoV-19 in an 83 Years Old Woman Experiencing Vaccine Induced Thrombosis with Thrombocytopenia Syndrome. *Vaccines (Basel).* 2022 Nov 30;10(12):2056. doi: 10.3390/vaccines10122056. PMID: 36560466; PMCID: PMC9781243.
- 14: Durand J, Dogné JM, Cohet C, Browne K, Gordillo-Marañón M, Piccolo L, Zaccaria C, Genov G. Safety Monitoring of COVID-19 Vaccines: Perspective from the European Medicines Agency. *Clin Pharmacol Ther.* 2023 Jun;113(6):1223-1234. doi: 10.1002/cpt.2828. Epub 2023 Feb 6. PMID: 36524423; PMCID: PMC9877988.
- 15: Buoninfante A, Andeweg A, Baker AT, Borad M, Crawford N, Dogné JM, Garcia-Azorin D, Greinacher A, Helfand R, Hviid A, Kochanek S, López-Fauqued M, Nazy I, Padmanabhan A, Pavord S, Prieto-Alhambra D, Tran H, Wandel Liminga U, Cavalieri M. Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination. *NPJ Vaccines.* 2022 Nov 9;7(1):141. doi: 10.1038/s41541-022-00569-8. PMID: 36351906; PMCID: PMC9643955.
- 16: Evrard J, Siriez R, Bouvy C, Favresse J, Yildiz H, Hainaut P, Mullier F, Dogné JM, Douxfils J. Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban-treated patients and healthy controls. *Res Pract Thromb Haemost.* 2022 Nov 4;6(7):e12804. doi: 10.1002/rth2.12804. PMID: 36349263; PMCID: PMC9634266.
- 17: Morimont L, Donis N, Bouvy C, Mullier F, Dogné JM, Douxfils J. Laboratory Testing for the Evaluation of Phenotypic Activated Protein C Resistance. *Semin Thromb Hemost.* 2022 Sep;48(6):680-689. doi: 10.1055/s-0042-1758162. Epub 2022 Oct 12. PMID: 36223771.
- 18: Favresse J, Gillot C, Bayart JL, David C, Simon G, Wauthier L, Closset M,

- Dogné JM, Douxfils J. Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. *J Med Virol*. 2023 Jan;95(1):e28164. doi: 10.1002/jmv.28164. Epub 2022 Oct 1. PMID: 36131356; PMCID: PMC9538323.
- 19: Morimont L, Jost M, Gaspard U, Foidart JM, Dogné JM, Douxfils J. Low Thrombin Generation in Users of a Contraceptive Containing Estetrol and Drospirenone. *J Clin Endocrinol Metab*. 2022 Dec 17;108(1):135-143. doi: 10.1210/clinem/dgac511. PMID: 36099501; PMCID: PMC9759169.
- 20: Morimont L, Donis N, Bouvy C, Mullier F, Dogné JM, Douxfils J. Laboratory Testing for the Evaluation of Phenotypic Activated Protein C Resistance. *Semin Thromb Hemost*. 2022 Sep;48(6):680-689. doi: 10.1055/s-0042-1753511. Epub 2022 Sep 2. PMID: 36055270.
- 21: Favresse J, Bayart JL, David C, Gillot C, Wieërs G, Roussel G, Sondag G, Elsen M, Eucher C, Dogné JM, Douxfils J. Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity. *Viruses*. 2022 Jul 28;14(8):1653. doi: 10.3390/v14081653. PMID: 36016276; PMCID: PMC9415151.
- 22: Gillot C, Favresse J, Maloteau V, Dogné JM, Douxfils J. Identification of SARS-CoV-2 Neutralizing Antibody with Pseudotyped Virus-based Test on HEK-293T hACE2 Cells. *Bio Protoc*. 2022 Apr 5;12(7):e4377. doi: 10.21769/BioProtoc.4377. PMID: 35530524; PMCID: PMC9018432.
- 23: Bayart JL, Degosserie J, Favresse J, Gillot C, Didembourg M, Djokoto HP, Verbelen V, Roussel G, Maschietto C, Mullier F, Dogné JM, Douxfils J. Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant. *Viruses*. 2022 Mar 22;14(4):654. doi: 10.3390/v14040654. PMID: 35458384; PMCID: PMC9031584.
- 24: Favresse J, Dogné JM, Douxfils J. Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster. *Clin Chem Lab Med*. 2022 Apr 25;60(7):e153-e156. doi: 10.1515/ccdm-2022-0323. PMID: 35452575.
- 25: Siriez R, Yildiz H, Bouvy C, Haguet H, Maloteau V, Hardy M, Mullier F, Dogné JM, Hainaut P, Douxfils J. The edoxaban-M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma. *Res Pract Thromb Haemost*. 2022 Apr 11;6(3):e12680. doi: 10.1002/rth2.12680. PMID: 35434470; PMCID: PMC9001858.
- 26: Morimont L, Leclercq C, Didembourg M, De Gottal É, Carlo A, Gaspard U, Dogné JM, Douxfils J. Analytical performance of the endogenous thrombin potential-based activated protein C resistance assay on the automated ST Genesia system. *Res Pract Thromb Haemost*. 2022 Apr 7;6(3):e12684. doi: 10.1002/rth2.12684. PMID: 35425874; PMCID: PMC8988860.
- 27: Favresse J, Bayart JL, David C, Dogné JM, Douxfils J. Nucleocapsid serum antigen determination in SARS-CoV-2 infected patients using the single molecule array technology and prediction of disease severity. *J Infect*. 2022 Apr;84(4):e4-e6. doi: 10.1016/j.jinf.2022.01.023. Epub 2022 Jan 21. PMID: 35074508; PMCID: PMC8779852.
- 28: Favresse J, Bayart JL, David C, Didembourg M, Gillot C, Dogné JM, Douxfils J. Spike vs. nucleocapsid serum antigens for COVID-19 diagnosis and severity assessment. *Clin Chem Lab Med*. 2022 Jan 11;60(5):e97-e100. doi: 10.1515/ccdm-2021-1244. PMID: 35007411.
- 29: Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. *Front Endocrinol (Lausanne)*. 2021 Dec 9;12:769187. doi: 10.3389/fendo.2021.769187. PMID: 34956081; PMCID: PMC8697849.
- 30: Douxfils J, Vayne C, Pouplard C, Lecompte T, Favresse J, Potier F, Gasser E, Mathieux V, Dogné JM, Gruel Y, Rollin J, Mullier F. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rationale for monitoring immunoglobulin G levels. *Haematologica*. 2021 Dec 1;106(12):3249-3252. doi: 10.3324/haematol.2021.279509. PMID: 34847660; PMCID: PMC8634183.
- 31: Gillot C, Favresse J, Maloteau V, Dogné JM, Douxfils J. Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects. *Viruses*. 2021 Nov 22;13(11):2329. doi: 10.3390/v13112329. PMID: 34835135; PMCID: PMC8621742.
- 32: Morimont L, Didembourg M, Haguet H, Modaffari É, Tillier M, Bouvy C, Lebreton A, Dogné JM, Douxfils J. Interlaboratory variability of activated protein C resistance using the ETP-based APC resistance assay. *Res Pract Thromb Haemost*. 2021 Nov 2;5(7):e12612. doi: 10.1002/rth2.12612. PMID: 34761157; PMCID: PMC8563922.
- 33: Bayart JL, Douxfils J, Gillot C, David C, Mullier F, Elsen M, Eucher C, Van Eeckhoudt S, Roy T, Gerin V, Wieers G, Laurent C, Closset M, Dogné JM, Favresse J. Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers. *Vaccines (Basel)*. 2021 Sep 28;9(10):1092. doi: 10.3390/vaccines9101092. PMID: 34696200; PMCID: PMC8540417.
- 34: Evrard J, Maloteau V, Dogné JM, Douxfils J. Simultaneous assessment of DOACs effect on clot formation and fibrinolysis with the FibWave. *Int J Lab Hematol*. 2022 Apr;44(2):e79-e83. doi: 10.1111/ijlh.13723. Epub 2021 Oct 5. PMID: 34613661.
- 35: Douxfils J, Gillot C, De Gottal É, Vandervinne S, Bayart JL, Dogné JM, Favresse J. Efficient Maternal to Neonate Transfer of Neutralizing Antibodies after SARS-CoV-2 Vaccination with BNT162b2: A Case-Report and Discussion of the Literature. *Vaccines (Basel)*. 2021 Aug 15;9(8):907. doi: 10.3390/vaccines9080907. PMID: 34452032; PMCID: PMC8402444.
- 36: Gillot C, Favresse J, Mullier F, Lecompte T, Dogné JM, Douxfils J. NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments. *Front*

Pharmacol. 2021 Aug 5;12:708302. doi: 10.3389/fphar.2021.708302. PMID: 34421600; PMCID: PMC8376580.

37: Douxfils J, Vayne C, Pouplard C, Lecompte T, Favresse J, Potier F, Gasser E, Mathieux V, Dogné JM, Gruel Y, Rollin J, Mullier F. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rationale for monitoring immunoglobulin G levels. *Haematologica*. 2021 Aug 12. doi: 10.3324/haematol.279509. Epub ahead of print. PMID: 34382387.

38: Favresse J, Gillot C, Di Chiaro L, Eucher C, Elsen M, Van Eckhoudt S, David C, Morimont L, Dogné JM, Douxfils J. Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2. *Viruses*. 2021 Jul 14;13(7):1364. doi: 10.3390/v13071364. PMID: 34372570; PMCID: PMC8309994.

39: Bahri P, Morales DR, Inoubli A, Dogné JM, Straus SMJM. Authors' Reply to Braillon and Martin's Comment on "Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)". *Drug Saf*. 2021 Sep;44(9):1011-1013. doi: 10.1007/s40264-021-01096-6. Epub 2021 Jul 29. PMID: 34324172.

40: Favresse J, Bayart JL, Mullier F, Elsen M, Eucher C, Van Eckhoudt S, Roy T, Wieers G, Laurent C, Dogné JM, Closset M, Douxfils J. Antibody titres decline 3-month post-vaccination with BNT162b2. *Emerg Microbes Infect*. 2021 Dec;10(1):1495-1498. doi: 10.1080/22221751.2021.1953403. PMID: 34232116; PMCID: PMC8300930.

41: Bayart JL, Morimont L, Closset M, Wieërs G, Roy T, Gerin V, Elsen M, Eucher C, Van Eckhoudt S, Ausselet N, David C, Mullier F, Dogné JM, Favresse J, Douxfils J. Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2. *Microorganisms*. 2021 Jun 21;9(6):1340. doi: 10.3390/microorganisms9061340. PMID: 34205564; PMCID: PMC8235462.

42: Douxfils J, Favresse J, Dogné JM, Lecompte T, Susen S, Cordonnier C, Lebreton A, Gosselin R, Sié P, Pernod G, Gruel Y, Nguyen P, Vayne C, Mullier F. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. *Thromb Res*. 2021 Jul;203:163-171. doi: 10.1016/j.thromres.2021.05.010. Epub 2021 May 15. PMID: 34029848; PMCID: PMC8123522.

43: Favresse J, Bayart JL, Mullier F, Dogné JM, Closset M, Douxfils J. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). *Clin Microbiol Infect*. 2021 Sep;27(9):1351.e5-1351.e7. doi: 10.1016/j.cmi.2021.05.004. Epub 2021 May 8. PMID: 33975007; PMCID: PMC8106520.

44: Favresse J, Eucher C, Elsen M, Gillot C, Van Eckhoudt S, Dogné JM, Douxfils J. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. *Microorganisms*. 2021 Mar 8;9(3):556. doi: 10.3390/microorganisms9030556. PMID: 33800489; PMCID: PMC8001517.

45: Haguët H, Douxfils J, Eucher C, Elsen M, Cadrobbi J, Tré-Hardy M, Dogné JM, Favresse J. Clinical performance of the Panbio assay for the detection of SARS-CoV-2 IgM and IgG in COVID-19 patients. *J Med Virol*. 2021 May;93(5):3277-3281. doi: 10.1002/jmv.26884. Epub 2021 Mar 1. PMID: 33599299; PMCID: PMC8014867.

46: Favresse J, Elsen M, Eucher C, Laffineur K, Van Eckhoudt S, Nicolas JB, Gillot C, Dogné JM, Douxfils J. Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients. *Clin Chem Lab Med*. 2020 Dec 18;59(5):e179-e183. doi: 10.1515/cclm-2020-1736. PMID: 33554588.

47: Favresse J, Gillot C, Oliveira M, Cadrobbi J, Elsen M, Eucher C, Laffineur K, Rosseels C, Van Eckhoudt S, Nicolas JB, Morimont L, Dogné JM, Douxfils J. Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection. *J Clin Med*. 2021 Jan 13;10(2):265. doi: 10.3390/jcm10020265. PMID: 33450853; PMCID: PMC7828347.

48: Favresse J, Bayart JL, Burlacu MC, Maiter D, Dogné JM, Douxfils J, Gruson D. Usefulness of a Non-Streptavidin Bead Technology to Overcome Biotin Interference: Proof of Principle with 25-OH Vitamin D, TSH, and FT4. *J Appl Lab Med*. 2021 Jul 7;6(4):1072-1077. doi: 10.1093/jalm/jfaa203. PMID: 33382887.

49: Evrard J, Morimont L, Didembourg M, Haguët H, Siriez R, Dogné JM, Douxfils J. Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance. *Int J Lab Hematol*. 2021 Aug;43(4):802-812. doi: 10.1111/ijlh.13427. Epub 2020 Dec 12. PMID: 33314736.

50: Gillot C, Douxfils J, Cadrobbi J, Laffineur K, Dogné JM, Elsen M, Eucher C, Melchionda S, Modaffari É, Tré-Hardy M, Favresse J. An Original ELISA-Based Multiplex Method for the Simultaneous Detection of 5 SARS-CoV-2 IgG Antibodies Directed against Different Antigens. *J Clin Med*. 2020 Nov 21;9(11):3752. doi: 10.3390/jcm9113752. PMID: 33233405; PMCID: PMC7700260.

51: Favresse J, Cadrobbi J, Eucher C, Elsen M, Laffineur K, Dogné JM, Douxfils J. Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins. *J Med Virol*. 2021 Apr;93(4):2262-2269. doi: 10.1002/jmv.26669. Epub 2020 Dec 1. PMID: 33200836; PMCID: PMC7753716.

52: Hardy M, Michaux I, Lessire S, Douxfils J, Dogné JM, Bareille M, Horlait G, Bulpa P, Chapelle C, Laporte S, Testa S, Jacqmin H, Lecompte T, Dive A, Mullier F. Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data. *Data Brief*. 2020 Dec;33:106519. doi: 10.1016/j.dib.2020.106519. Epub 2020 Nov 10. PMID: 33200086; PMCID: PMC7654236.

53: Hardy M, Michaux I, Lessire S, Douxfils J, Dogné JM, Bareille M, Horlait G, Bulpa P, Chapelle C, Laporte S, Testa S, Jacqmin H, Lecompte T, Dive A, Mullier F. Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A

prospective longitudinal observational study. *Thromb Res.* 2021 Jan;197:20-23. doi: 10.1016/j.thromres.2020.10.025. Epub 2020 Oct 24. PMID: 33161283; PMCID: PMC7585359.

54: Bahri P, Morales DR, Inoubli A, Dogné JM, Straus SMJM. Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET). *Drug Saf.* 2021 Feb;44(2):193-209. doi: 10.1007/s40264-020-01005-3. Epub 2020 Oct 30. PMID: 33125664; PMCID: PMC7847429.

55: Evrard J, Hardy M, Dogné JM, Lessire S, Maloteau V, Mullier F, Douxfils J. Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing. *Int J Lab Hematol.* 2021 Feb;43(1):e48-e51. doi: 10.1111/ijlh.13356. Epub 2020 Oct 10. PMID: 33037773.

56: Hardy M, Douxfils J, Dogné JM, Lessire S, Chatelain B, Testa S, Gouin-Thibault I, Gruel Y, Lecompte T, Mullier F. Apport du laboratoire d'hémostase dans la gestion du risque thrombotique associé au Covid-19 [Management of the thrombotic risk associated with COVID-19: what is the role of the hemostasis laboratory?]. *Ann Biol Clin (Paris).* 2020 Oct 1;78(5):471-481. French. doi: 10.1684/abc.2020.1581. PMID: 33026344.

57: Thémans P, Belkhir L, Dauby N, Yombi JC, De Greef J, Delongie KA, Vandeputte M, Nasreddine R, Wittebole X, Wuillaume F, Lescrainier C, Verlinden V, Kiridis S, Dogné JM, Hamdani J, Wallemacq P, Musuamba FT. Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. *Eur J Drug Metab Pharmacokinet.* 2020 Dec;45(6):703-713. doi: 10.1007/s13318-020-00648-y. PMID: 32968954; PMCID: PMC7511144.

58: Siriez R, Dogné JM, Gosselin R, Laloy J, Mullier F, Douxfils J. Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory. *Int J Lab Hematol.* 2021 Feb;43(1):7-20. doi: 10.1111/ijlh.13342. Epub 2020 Sep 18. PMID: 32946681.

59: Mairesse A, Favresse J, Euchet C, Elsen M, Tré-Hardy M, Haventith C, Gruson D, Dogné JM, Douxfils J, Göbbels P. High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies. *Clin Biochem.* 2020 Dec;86:23-27. doi: 10.1016/j.clinbiochem.2020.08.009. Epub 2020 Aug 25. PMID: 32858061; PMCID: PMC7445483.

60: Morimont L, Dogné JM, Douxfils J. Letter to the Editors-in-Chief in response to the article of Abou-Ismaïl, et al. entitled "Estrogen and thrombosis: A bench to bedside review" (*Thrombosis Research* 192 (2020) 40-51). *Thromb Res.* 2020 Sep;193:221-223. doi: 10.1016/j.thromres.2020.08.006. Epub 2020 Aug 5. PMID: 32798963.

61: Hardy M, Lessire S, Kasikci S, Baudar J, Guldenpfennig M, Collard A, Dogné JM, Chatelain B, Jacqmin H, Lecompte T, Mullier F. Effects of Time-Interval since Blood Draw and of Anticoagulation on Platelet Testing (Count, Indices and Impedance Aggregometry): A Systematic Study with Blood from Healthy Volunteers. *J Clin Med.* 2020 Aug 4;9(8):2515. doi: 10.3390/jcm9082515. PMID: 32759828; PMCID: PMC7465339.

62: Haguet H, Bouvy C, Delvigne AS, Modaffari E, Wannez A, Sonveaux P, Dogné JM, Douxfils J. The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. *Front Pharmacol.* 2020 Jul 3;11:1007. doi: 10.3389/fphar.2020.01007. PMID: 32719607; PMCID: PMC7350860.

63: Tré-Hardy M, Wilmet A, Beukinga I, Favresse J, Dogné JM, Douxfils J, Blairon L. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies. *J Med Virol.* 2021 Feb;93(2):803-811. doi: 10.1002/jmv.26303. Epub 2020 Jul 27. PMID: 32667733; PMCID: PMC7405491.

64: Favresse J, Euchet C, Elsen M, Laffineur K, Dogné JM, Douxfils J. Response of anti-SARS-CoV-2 total antibodies to nucleocapsid antigen in COVID-19 patients: a longitudinal study. *Clin Chem Lab Med.* 2020 Sep 25;58(10):e193-e196. doi: 10.1515/cclm-2020-0962. PMID: 32639942.

65: Thémans P, Dauby N, Schrooyen L, Lebout F, Delforge M, Nasreddine R, Libois A, Payen MC, Konopnicki D, Wuillaume F, Lescrainier C, Verlinden V, Dogné JM, Hamdani J, Musuamba FT. Model informed dosing of hydroxychloroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps. *Br J Clin Pharmacol.* 2021 Feb;87(2):674-682. doi: 10.1111/bcp.14436. Epub 2020 Jul 19. PMID: 32559820.

66: Favresse J, Euchet C, Elsen M, Graux C, Goebels P, Laffineur K, Nicolas JB, Dogné JM, Douxfils J. Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia. *Br J Haematol.* 2020 Aug;190(4):e187-e189. doi: 10.1111/bjh.16954. Epub 2020 Jul 9. PMID: 32557555; PMCID: PMC7323137.

67: Favresse J, Euchet C, Elsen M, Tré-Hardy M, Dogné JM, Douxfils J. Clinical Performance of the Elecsys Electrochemiluminescent Immunoassay for the Detection of SARS-CoV-2 Total Antibodies. *Clin Chem.* 2020 Aug 1;66(8):1104-1106. doi: 10.1093/clinchem/hvaa131. PMID: 32484887; PMCID: PMC7314109.

68: Tré-Hardy M, Wilmet A, Beukinga I, Dogné JM, Douxfils J, Blairon L. Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody. *Clin Chem Lab Med.* 2020 Jul 28;58(8):1357-1364. doi: 10.1515/cclm-2020-0594. PMID: 32447328.

69: Jacqmin H, Chatelain B, Louveaux Q, Jacqmin P, Dogné JM, Graux C, Mullier F. Clustering and Kernel Density Estimation for Assessment of Measurable Residual Disease by Flow Cytometry. *Diagnostics (Basel).* 2020 May 18;10(5):317. doi: 10.3390/diagnostics10050317. PMID: 32443428; PMCID: PMC7277972.

- 70: Haguet H, Graux C, Mullier F, Dogné JM, Douxfils J. Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis. *Cancers (Basel)*. 2020 May 15;12(5):1242. doi: 10.3390/cancers12051242. PMID: 32429056; PMCID: PMC7281573.
- 71: Tré-Hardy M, Blairon L, Wilmet A, Beukinga I, Malonne H, Dogné JM, Douxfils J. The role of serology for COVID-19 control: Population, kinetics and test performance do matter. *J Infect*. 2020 Aug;81(2):e91-e92. doi: 10.1016/j.jinf.2020.05.019. Epub 2020 May 15. PMID: 32417311; PMCID: PMC7228733.
- 72: Favresse J, Bayart JL, Stoefs A, Gheldof D, Douxfils J, Dogné JM, Gruson D. Neutralization of biotin interference: preliminary evaluation of the VeraTest Biotin™, VeraPrep Biotin™ and BioT-Filter®. *Clin Chem Lab Med*. 2020 Jul 28;58(8):e130-e133. doi: 10.1515/cclm-2019-1121. PMID: 32092039.
- 73: Morimont L, Bouvy C, Delvigne AS, Dogné JM, Douxfils J. Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance. *J Thromb Haemost*. 2020 Apr;18(4):895-904. doi: 10.1111/jth.14745. Epub 2020 Mar 2. PMID: 31984653.
- 74: Correia Pinheiro L, Durand J, Dogné JM. An Application of Machine Learning in Pharmacovigilance: Estimating Likely Patient Genotype From Phenotypical Manifestations of Fluoropyrimidine Toxicity. *Clin Pharmacol Ther*. 2020 Apr;107(4):944-947. doi: 10.1002/cpt.1789. Epub 2020 Feb 27. PMID: 31955411; PMCID: PMC7158217.
- 75: Siriez R, Alpan L, Elasaad K, Devel P, Laloy J, Dogné JM, Douxfils J. Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method. *J Thromb Thrombolysis*. 2020 Apr;49(3):395-403. doi: 10.1007/s11239-019-02030-5. PMID: 31925664.
- 76: Douxfils J, Morimont L, Delvigne AS, Devel P, Masereel B, Haguet H, Bouvy C, Dogné JM. Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need. *Clin Chem Lab Med*. 2020 Jan 28;58(2):294-305. doi: 10.1515/cclm-2019-0471. PMID: 31444961.
- 77: Devalet B, Wannez A, Bailly N, Alpan L, Gheldof D, Douxfils J, Bihin B, Chatelain B, Dogné JM, Chatelain C, Mullier F. Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab: Focus on platelet extracellular vesicles. *Medicine (Baltimore)*. 2019 Jul;98(27):e16164. doi: 10.1097/MD.00000000000016164. PMID: 31277120; PMCID: PMC6635286.
- 78: Douxfils J, Morimont L, Bouvy C, de Saint-Hubert M, Devalet B, Devroye C, Dincq AS, Dogné JM, Guldenpfennig M, Baudar J, Larock AS, Lessire S, Mullier F. Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application. *J Thromb Haemost*. 2019 Aug;17(8):1273-1287. doi: 10.1111/jth.14470. Epub 2019 May 31. PMID: 31063645; PMCID: PMC6852561.
- 79: Wannez A, Devalet B, Chatelain B, Chatelain C, Dogné JM, Mullier F. Extracellular Vesicles in Red Blood Cell Concentrates: An Overview. *Transfus Med Rev*. 2019 Apr;33(2):125-130. doi: 10.1016/j.tmr.2019.02.002. Epub 2019 Feb 23. PMID: 30910256.
- 80: Evrard J, Siriez R, Morimont L, Thémans P, Laloy J, Bouvy C, Gheldof D, Mullier F, Dogné JM, Douxfils J. Optimal wavelength for the clot waveform analysis: Determination of the best resolution with minimal interference of the reagents. *Int J Lab Hematol*. 2019 Jun;41(3):316-324. doi: 10.1111/ijlh.12975. Epub 2019 Feb 7. PMID: 30730600.
- 81: Siriez R, Evrard J, Dogné JM, Pochet L, Bouvy C, Lessire S, Mullier F, Douxfils J. Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. *Int J Lab Hematol*. 2019 Apr;41(2):250-261. doi: 10.1111/ijlh.12963. Epub 2019 Jan 3. PMID: 30604921.
- 82: Laloy J, Haguet H, Alpan L, Raichman D, Dogné JM, Lellouche JP. Impact of functional inorganic nanotubes F-INTS-WS<sub>2</sub> on hemolysis, platelet function and coagulation. *Nano Converg*. 2018 Oct 30;5(1):31. doi: 10.1186/s40580-018-0162-1. PMID: 30467733; PMCID: PMC6206311.
- 83: Sennesael AL, Larock AS, Douxfils J, Elens L, Stillemans G, Wiesen M, Taubert M, Dogné JM, Spinewine A, Mullier F. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. *Thromb J*. 2018 Nov 12;16:28. doi: 10.1186/s12959-018-0183-3. PMID: 30455596; PMCID: PMC6231259.
- 84: Palazzo C, Laloy J, Delvigne AS, Nys G, Fillet M, Dogné JM, Pequeux C, Foidart JM, Evrard B, Piel G. Development of injectable liposomes and drug-in-cyclodextrin-in-liposome formulations encapsulating estetrol to prevent cerebral ischemia of premature babies. *Eur J Pharm Sci*. 2019 Jan 15;127:52-59. doi: 10.1016/j.ejps.2018.10.006. Epub 2018 Oct 9. PMID: 30308312.
- 85: Vatzaki E, Straus S, Dogné JM, Garcia Burgos J, Girard T, Martelletti P. Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation. *J Headache Pain*. 2018 Aug 14;19(1):68. doi: 10.1186/s10194-018-0898-3. PMID: 30109437; PMCID: PMC6092728.
- 86: Minet V, Evrard J, Vancaeynest C, Dogné JM, Mullier F, Pochet L. Development and validation of a liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of serotonin and thromboxane B2 from activated platelets. *Int J Lab Hematol*. 2018 Dec;40(6):663-671. doi: 10.1111/ijlh.12901. Epub 2018 Jul 17. PMID: 30019376.
- 87: Bouvy C, Wannez A, George F, Graux C, Chatelain C, Dogné JM. Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study. *Biomark Cancer*. 2018 Jun 18;10:1179299X18781095. doi: 10.1177/1179299X18781095. PMID: 29977116; PMCID: PMC6024490.

- 88: Kälviäinen R, Straus S, Dogne JM, Bakchine S, Haas M. Reducing valproate use in women with epilepsy. *Lancet Neurol*. 2018 Jul;17(7):580-581. doi: 10.1016/S1474-4422(18)30172-8. PMID: 29914703.
- 89: Siriez R, Evrard J, Dogné JM, Pochet L, Gheldof D, Chatelain B, Mullier F, Douxfils J. Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide. *Thromb Haemost*. 2018 Jul;118(7):1203-1214. doi: 10.1055/s-0038-1657772. Epub 2018 Jun 11. PMID: 29890519.
- 90: Sennesael AL, Larock AS, Devalet B, Mathieux V, Verschuren F, Muschart X, Dalleur O, Dogné JM, Spinewine A. Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study. *Br J Clin Pharmacol*. 2018 Jul;84(7):1544-1556. doi: 10.1111/bcp.13580. Epub 2018 Apr 17. PMID: 29522647; PMCID: PMC6005616.
- 91: Postigo R, Brosch S, Slattery J, van Haren A, Dogné JM, Kurz X, Candore G, Domergue F, Arlett P. EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection. *Drug Saf*. 2018 Jul;41(7):665-675. doi: 10.1007/s40264-018-0647-1. PMID: 29520645; PMCID: PMC5990579.
- 92: Haguet H, Douxfils J, Chatelain C, Graux C, Mullier F, Dogné JM. BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis? *TH Open*. 2018 Feb 14;2(1):e68-e88. doi: 10.1055/s-0038-1624566. PMID: 31249931; PMCID: PMC6524858.
- 93: Courtois A, Makrygiannis G, Cheramy-Bien JP, Purnelle A, Pirotte B, Dogne JM, Hanson J, Defraigne JO, Drion P, Sakalihasan N. Therapeutic Applications of Prostaglandins and Thromboxane A2 Inhibitors in Abdominal Aortic Aneurysms. *Curr Drug Targets*. 2018;19(11):1247-1255. doi: 10.2174/1389450119666171227224314. PMID: 29284385.
- 94: Lozano O, Colaux JL, Laloy J, Alpan L, Dogné JM, Lucas S. Fast, asymmetric and nonhomogeneous clearance of SiC nanoaerosol assessed by micro-particle-induced x-ray emission. *Nanomedicine (Lond)*. 2018 Jan;13(2):145-155. doi: 10.2217/nmm-2017-0245. Epub 2017 Nov 27. PMID: 29173016.
- 95: Bouvy C, Wannez A, Laloy J, Chatelain C, Dogné JM. Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo. *Leuk Res*. 2017 Nov;62:70-76. doi: 10.1016/j.leukres.2017.09.014. Epub 2017 Sep 25. PMID: 28987820.
- 96: Maignen F, Hauben M, Dogné JM. A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionality. *Ther Adv Drug Saf*. 2017 Jul;8(7):231-244. doi: 10.1177/2042098617704143. Epub 2017 May 5. PMID: 28845231; PMCID: PMC5564890.
- 97: Vornicu O, Larock AS, Dincq AS, Douxfils J, Dogné JM, Mullier F, Lessire S. Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. *Expert Opin Biol Ther*. 2017 Oct;17(10):1275-1296. doi: 10.1080/14712598.2017.1349749. Epub 2017 Jul 20. PMID: 28728489.
- 98: Sennesael AL, Exner T, Chatelain B, Lessire S, Larock AS, Vancaerneyest C, Pochet L, Dogné JM, Spinewine A, Mullier F, Douxfils J. An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. *Thromb Res*. 2017 Sep;157:29-37. doi: 10.1016/j.thromres.2017.06.034. Epub 2017 Jun 28. PMID: 28686914.
- 99: Wannez A, Devalet B, Bouvy C, Laloy J, Bihin B, Chatelain B, Chatelain C, Dogné JM, Mullier F. Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. *Thromb Res*. 2017 Aug;156:142-148. doi: 10.1016/j.thromres.2017.06.013. Epub 2017 Jun 9. PMID: 28646725.
- 100: Sabor L, Raphaël M, Dogné JM, Mullier F, Douxfils J. Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels. *Thromb Res*. 2017 Aug;156:36-38. doi: 10.1016/j.thromres.2017.05.024. Epub 2017 May 25. PMID: 28582639.
- 101: Dubois V, Dincq AS, Douxfils J, Ickx B, Samama CM, Dogné JM, Gourdin M, Chatelain B, Mullier F, Lessire S. Perioperative management of patients on direct oral anticoagulants. *Thromb J*. 2017 May 15;15:14. doi: 10.1186/s12959-017-0137-1. PMID: 28515674; PMCID: PMC5433145.
- 102: Karim R, Palazzo C, Laloy J, Delvigne AS, Vanslambrouck S, Jerome C, Lepeltier E, Orange F, Dogne JM, Evrard B, Passirani C, Piel G. Development and evaluation of injectable nanosized drug delivery systems for apigenin. *Int J Pharm*. 2017 Nov 5;532(2):757-768. doi: 10.1016/j.ijpharm.2017.04.064. Epub 2017 Apr 27. PMID: 28456651.
- 103: Minet V, Dogné JM, Mullier F. Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review. *Molecules*. 2017 Apr 11;22(4):617. doi: 10.3390/molecules22040617. PMID: 28398258; PMCID: PMC6153750.
- 104: Devalet B, Wannez A, Bailly N, Alpan L, Gheldof D, Douxfils J, Deneyz V, Bihin B, Chatelain B, Dogné JM, Chatelain C, Mullier F. Application of a clot-based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates. *Blood Transfus*. 2018 Feb;16(2):163-172. doi: 10.2450/2017.0230-16. Epub 2017 Mar 9. PMID: 28287378; PMCID: PMC5839613.
- 105: Gheldof D, Haguet H, Dogné JM, Bouvy C, Graux C, George F, Sonet A, Chatelain C, Chatelain B, Mullier F. Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia. *J Thromb Thrombolysis*. 2017 Feb;43(2):224-232. doi: 10.1007/s11239-016-1471-z. PMID: 28074413.
- 106: Frère A, Baroni A, Hendrick E, Delvigne AS, Orange F, Peulen O, Dakwar GR, Diricq J, Dubois P, Evrard B, Remaut K, Braeckmans K, De Smedt SC, Laloy J, Dogné JM, Feller G, Mespouille L, Mottet D, Piel G. PEGylated and Functionalized Aliphatic Polycarbonate Polyplex Nanoparticles for Intravenous Administration of

- HDAC5 siRNA in Cancer Therapy. *ACS Appl Mater Interfaces*. 2017 Jan 25;9(3):2181-2195. doi: 10.1021/acsami.6b15064. Epub 2017 Jan 11. PMID: 28029254.
- 107: Salmonson T, Dogné JM, Janssen H, Garcia Burgos J, Blake P. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA). *Eur Heart J Cardiovasc Pharmacother*. 2017 Jan;3(1):42-47. doi: 10.1093/ehjcvp/pww032. Epub 2016 Dec 25. PMID: 28025213; PMCID: PMC5216197.
- 108: Dincq AS, Lessire S, Chatelain B, Gourdin M, Dogné JM, Mullier F, Douxfils J. Impact of the Direct Oral Anticoagulants on Activated Clotting Time. *J Cardiothorac Vasc Anesth*. 2017 Feb;31(1):e24-e27. doi: 10.1053/j.jvca.2016.09.002. Epub 2016 Sep 7. PMID: 27884610.
- 109: Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogné JM. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. *Expert Opin Drug Saf*. 2017 Jan;16(1):5-12. doi: 10.1080/14740338.2017.1261824. Epub 2016 Nov 28. PMID: 27852118.
- 110: Lessire S, Douxfils J, Pochet L, Dincq AS, Larock AS, Gourdin M, Dogné JM, Chatelain B, Mullier F. Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging. *Clin Appl Thromb Hemost*. 2018 Jan;24(1):129-138. doi: 10.1177/1076029616675968. Epub 2016 Nov 3. PMID: 27811211; PMCID: PMC6714623.
- 111: Douxfils J, Haguet H, Dogné JM. Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia-Reply. *JAMA Oncol*. 2016 Jun 1;2(6):829. doi: 10.1001/jamaoncol.2016.1011. PMID: 27281625.
- 112: Romero M, Leon-Gomez E, Lobysheva I, Rath G, Dogné JM, Feron O, Dessy C. Effects of BM-573 on Endothelial Dependent Relaxation and Increased Blood Pressure at Early Stages of Atherosclerosis. *PLoS One*. 2016 Mar 28;11(3):e0152579. doi: 10.1371/journal.pone.0152579. PMID: 27019366; PMCID: PMC4809599.
- 113: Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné JM. Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2016 May 1;2(5):625-632. doi: 10.1001/jamaoncol.2015.5932. PMID: 26847662.
- 114: Bouckaert C, Serra S, Rondelet G, Dolušić E, Wouters J, Dogné JM, Frédéric R, Pochet L. Synthesis, evaluation and structure-activity relationship of new 3-carboxamide coumarins as FXIIa inhibitors. *Eur J Med Chem*. 2016 Mar 3;110:181-94. doi: 10.1016/j.ejmech.2016.01.023. Epub 2016 Jan 16. PMID: 26827162.
- 115: Douxfils J, Chatelain B, Chatelain C, Dogné JM, Mullier F. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide. *Thromb Haemost*. 2016 Jan;115(2):368-81. doi: 10.1160/TH15-05-0415. Epub 2015 Oct 29. PMID: 26510969.
- 116: Nchimi A, Courtois A, El Hachemi M, Touat Z, Drion P, Withofs N, Warnock G, Bahri MA, Dogné JM, Cheramy-Bien JP, Schoysman L, Joskin J, Michel JB, Defraigne JO, Plenevaux A, Sakalihan N. Multimodality imaging assessment of the deleterious role of the intraluminal thrombus on the growth of abdominal aortic aneurysm in a rat model. *Eur Radiol*. 2016 Jul;26(7):2378-86. doi: 10.1007/s00330-015-4010-y. Epub 2015 Sep 22. PMID: 26396112.
- 117: Lessire S, Douxfils J, Baudar J, Bailly N, Dincq AS, Gourdin M, Dogné JM, Chatelain B, Mullier F. Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. *Thromb Res*. 2015 Sep;136(3):693-6. doi: 10.1016/j.thromres.2015.07.018. Epub 2015 Jul 22. PMID: 26251077.
- 118: Sennesael AL, Dogné JM, Spinewine A. Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment. *JAMA Intern Med*. 2015 Oct;175(10):1608-9. doi: 10.1001/jamainternmed.2015.3589. PMID: 26237648.
- 119: Watelet JB, Dogné JM, Mullier F. Remodeling and Repair in Rhinosinusitis. *Curr Allergy Asthma Rep*. 2015 Jun;15(6):34. doi: 10.1007/s11882-015-0531-3. PMID: 26141576.
- 120: Douxfils J, Mani H, Minet V, Devalet B, Chatelain B, Dogné JM, Mullier F. Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. *Biomed Res Int*. 2015;2015:345138. doi: 10.1155/2015/345138. Epub 2015 May 19. PMID: 26090400; PMCID: PMC4452246.
- 121: Tantra R, Bouwmeester H, Bolea E, Rey-Castro C, David CA, Dogné JM, Jarman J, Laborda F, Laloy J, Robinson KN, Undas AK, van der Zande M. Suitability of analytical methods to measure solubility for the purpose of nanoregulation. *Nanotoxicology*. 2016;10(2):173-84. doi: 10.3109/17435390.2015.1038661. Epub 2015 May 22. PMID: 26001188.
- 122: Douxfils J, Mullier F, Dogné JM. Dose tailoring of dabigatran etexilate: obvious or excessive? *Expert Opin Drug Saf*. 2015 Aug;14(8):1283-9. doi: 10.1517/14740338.2015.1049995. Epub 2015 May 21. PMID: 25994994.
- 123: Minet V, Bailly N, Dogné JM, Mullier F. Platelet microparticle generation assay for heparin-induced thrombocytopenia diagnosis: How should we express the results? *Thromb Res*. 2015 Jul;136(1):175-7. doi: 10.1016/j.thromres.2015.04.035. Epub 2015 May 1. PMID: 25976450.
- 124: Mullier F, Douxfils J, Tamigniau A, Dogné JM, Horellou MH, Flaujac C, Chatelain B, Goffinet C, Samama MM, Gouin-Thibault I. Anticoagulants directs oraux : actualités pour les biologistes [Non-VKA oral anticoagulants: an update for the clinical biologists]. *Ann Biol Clin (Paris)*. 2015 May-Jun;73(3):333-44. French. doi: 10.1684/abc.2015.1025. PMID: 25857818.

- 125: de Fays L, Van Malderen K, De Smet K, Sawchik J, Verlinden V, Hamdani J, Dogné JM, Dan B. Use of paracetamol during pregnancy and child neurological development. *Dev Med Child Neurol*. 2015 Aug;57(8):718-24. doi: 10.1111/dmcn.12745. Epub 2015 Apr 7. PMID: 25851072.
- 126: Devalet B, Mullier F, Chatelain B, Dogné JM, Chatelain C. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. *Eur J Haematol*. 2015 Sep;95(3):190-8. doi: 10.1111/ejh.12543. Epub 2015 Mar 26. PMID: 25753400.
- 127: Douxfils J, Chatelain B, Hjemdahl P, Devalet B, Sennesael AL, Wallemacq P, Rönquist-Nii Y, Pohanka A, Dogné JM, Mullier F. Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. *Thromb Res*. 2015 May;135(5):852-60. doi: 10.1016/j.thromres.2015.02.020. Epub 2015 Feb 26. PMID: 25743887.
- 128: Larock AS, Mullier F, Douxfils J, Dogné JM, Spinewine A. Criteria for prescribing dabigatrin etexilate and rivaroxaban really appropriate? Authors' reply. *Ann Pharmacother*. 2015 Jan;49(1):155. doi: 10.1177/1060028014556118. PMID: 25524933.
- 129: Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Rönquist-Nii Y, Pohanka A, Gourdin M, Chatelain B, Dogné JM, Mullier F. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. *Thromb Haemost*. 2015 Apr;113(4):862-9. doi: 10.1160/TH14-09-0808. Epub 2014 Dec 18. PMID: 25519251.
- 130: Dincq AS, Lessire S, Douxfils J, Dogné JM, Gourdin M, Mullier F. Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting. *Biomed Res Int*. 2014;2014:385014. doi: 10.1155/2014/385014. Epub 2014 Sep 3. PMID: 25276784; PMCID: PMC4168027.
- 131: Bouvy C, Gheldof D, Chatelain C, Mullier F, Dogné JM. Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer. *J Extracell Vesicles*. 2014 Jul 11;3. doi: 10.3402/jev.v3.24400. PMID: 25045423; PMCID: PMC4095764.
- 132: Lessire S, Dincq AS, Douxfils J, Devalet B, Nicolas JB, Spinewine A, Larock AS, Dogné JM, Gourdin M, Mullier F. Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants. *Biomed Res Int*. 2014;2014:616405. doi: 10.1155/2014/616405. Epub 2014 Jun 16. Erratum in: *Biomed Res Int*. 2014;2014:347031. multiple author names corrected. PMID: 25032218; PMCID: PMC4084591.
- 133: Larock AS, Mullier F, Sennesael AL, Douxfils J, Devalet B, Chatelain C, Dogné JM, Spinewine A. Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. *Ann Pharmacother*. 2014 Oct;48(10):1258-68. doi: 10.1177/1060028014540868. Epub 2014 Jun 30. PMID: 24982310.
- 134: Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster JY, Hainaut P, Bruyère O, Dogné JM. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. *J Am Heart Assoc*. 2014 Jun 6;3(3):e000515. doi: 10.1161/JAHA.113.000515. PMID: 24906369; PMCID: PMC4309041.
- 135: Gheldof D, Chatelain C, Dogné JM, Mullier F. Microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. *Thromb Res*. 2014 Jul;134(1):213-4. doi: 10.1016/j.thromres.2014.05.001. Epub 2014 May 10. PMID: 24861693.
- 136: Laloy J, Lozano O, Alpan L, Mejia J, Toussaint O, Masereel B, Dogné JM, Lucas S. Can TiC nanoparticles produce toxicity in oral administration to rats? *Toxicol Rep*. 2014 May 12;1:172-187. doi: 10.1016/j.toxrep.2014.03.004. PMID: 28962237; PMCID: PMC5598454.
- 137: Garin P, Peerbaccus Y, Mullier F, Gheldof D, Dogné JM, Putz L, Van Damme JP. Platelet-rich fibrin (PRF): an autologous packing material for middle ear microsurgery. *B-ENT*. 2014;10(1):27-34. PMID: 24765826.
- 138: Arlett P, Portier G, de Lisa R, Blake K, Wathion N, Dogné JM, Spooner A, Raine J, Rasi G. Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee. *Nat Rev Drug Discov*. 2014 May;13(5):395-7. doi: 10.1038/nrd3713-c1. Epub 2014 Apr 22. PMID: 24751815.
- 139: Devalet B, Mullier F, Chatelain B, Dogné JM, Chatelain C. The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review. *J Extracell Vesicles*. 2014 Mar 24;3. doi: 10.3402/jev.v3.23304. PMID: 24672668; PMCID: PMC3965713.
- 140: Tamigniau A, Douxfils J, Nicolas JB, Devalet B, Larock AS, Spinewine A, Dincq AS, Lessire S, Gourdin M, Watelet JB, Mathieux V, Chatelain C, Dogné JM, Chatelain B, Mullier F. Pourquoi, quand et comment doser les nouveaux anticoagulants oraux? [Why, when and how to monitor new oral anticoagulants]. *Rev Med Suisse*. 2014 Feb 5;10(416):326-33. French. PMID: 24624625.
- 141: Laloy J, Minet V, Alpan L, Mullier F, Beken S, Toussaint O, Lucas S, Dogné JM. Impact of Silver Nanoparticles on Haemolysis, Platelet Function and Coagulation. *Nanobiomedicine (Rij)*. 2014 Jan 1;1:4. doi: 10.5772/59346. PMID: 30023015; PMCID: PMC6029236.
- 142: Douxfils J, Tamigniau A, Chatelain B, Goffinet C, Dogné JM, Mullier F. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. *Thromb J*. 2014 Nov 4;12:24. doi: 10.1186/1477-9560-12-24. PMID: 25750588; PMCID: PMC4351835.
- 143: Gheldof D, Mullier F, Bailly N, Devalet B, Dogné JM, Chatelain B, Chatelain C. Microparticle bearing tissue factor: a link between promyelocytic cells and hypercoagulable state. *Thromb Res*. 2014 Mar;133(3):433-9. doi: 10.1016/j.thromres.2013.11.008. Epub 2013 Nov 16. PMID: 24290525.

- 144: Mullier F, Vanpee D, Jamart J, Dubuc E, Bailly N, Douxfils J, Chatelain C, Dogné JM, Chatelain B. Comparison of five D-dimer reagents and application of an age-adjusted cut-off for the diagnosis of venous thromboembolism in emergency department. *Blood Coagul Fibrinolysis*. 2014 Jun;25(4):309-15. doi: 10.1097/MBC.000000000000020. PMID: 24247319.
- 145: Maignen F, Hauben M, Hung E, Holle LV, Dogne JM. A conceptual approach to the masking effect of measures of disproportionality. *Pharmacoepidemiol Drug Saf*. 2014 Feb;23(2):208-17. doi: 10.1002/pds.3530. Epub 2013 Nov 15. PMID: 24243699.
- 146: Maignen F, Hauben M, Hung E, Van Holle L, Dogne JM. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. *Pharmacoepidemiol Drug Saf*. 2014 Feb;23(2):195-207. doi: 10.1002/pds.3529. Epub 2013 Nov 15. PMID: 24243665.
- 147: Hardij J, Cecchet F, Berquand A, Gheldof D, Chatelain C, Mullier F, Chatelain B, Dogné JM. Characterisation of tissue factor-bearing extracellular vesicles with AFM: comparison of air-tapping-mode AFM and liquid Peak Force AFM. *J Extracell Vesicles*. 2013 Aug 27;2. doi: 10.3402/jev.v2i0.21045. PMID: 24223257; PMCID: PMC3823107.
- 148: Petri MH, Tellier C, Michiels C, Ellertsen I, Dogné JM, Bäck M. Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells. *Biochem Biophys Res Commun*. 2013 Nov 15;441(2):393-8. doi: 10.1016/j.bbrc.2013.10.078. Epub 2013 Oct 23. PMID: 24161392.
- 149: Draoui N, Schicke O, Fernandes A, Drozak X, Nahra F, Dumont A, Douxfils J, Hermans E, Dogné JM, Corbau R, Marchand A, Chaltin P, Sonveaux P, Feron O, Riant O. Synthesis and pharmacological evaluation of coumarins as a new antitumor treatment targeting lactate transport in cancer cells. *Bioorg Med Chem*. 2013 Nov 15;21(22):7107-17. doi: 10.1016/j.bmc.2013.09.010. Epub 2013 Sep 13. PMID: 24095010.
- 150: Gheldof D, Hardij J, Cecchet F, Chatelain B, Dogné JM, Mullier F. Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles. *J Extracell Vesicles*. 2013 Mar 18;2. doi: 10.3402/jev.v2i0.19728. PMID: 24009889; PMCID: PMC3760633.
- 151: Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogné JM, Mullier F. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. *Thromb Haemost*. 2013 Oct;110(4):723-31. doi: 10.1160/TH13-04-0274. Epub 2013 Jul 11. PMID: 23846172.
- 152: Gheldof D, Mullier F, Chatelain B, Dogné JM, Chatelain C. Inhibition of tissue factor pathway inhibitor increases the sensitivity of thrombin generation assay to procoagulant microvesicles. *Blood Coagul Fibrinolysis*. 2013 Jul;24(5):567-72. doi: 10.1097/MBC.0b013e328360a56e. PMID: 23807485.
- 153: Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. *Thromb Haemost*. 2013 Aug;110(2):283-94. doi: 10.1160/TH12-12-0898. Epub 2013 Jun 13. PMID: 23765180.
- 154: Bambi-Nyanguile SM, Hanson J, Ooms A, Alpan L, Kolh P, Dogné JM, Pirotte B. Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A<sub>2</sub> receptor antagonists. *Eur J Med Chem*. 2013 Jul;65:32-40. doi: 10.1016/j.ejmech.2013.04.033. Epub 2013 Apr 23. PMID: 23688698.
- 155: Laloy J, Mullier F, Alpan L, Mejia J, Lucas S, Chatelain B, Toussaint O, Masereel B, Rolin S, Dogné JM. A comparison of six major platelet functional tests to assess the impact of carbon nanomaterials on platelet function: a practical guide. *Nanotoxicology*. 2014 Mar;8(2):220-32. doi: 10.3109/17435390.2013.788750. Epub 2013 Apr 15. PMID: 23521718.
- 156: Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. *Thromb Res*. 2012 Dec;130(6):956-66. doi: 10.1016/j.thromres.2012.09.004. Epub 2012 Sep 21. PMID: 23006523.
- 157: Gourdin M, Dubois P, Mullier F, Chatelain B, Dogné JM, Marchandise B, Jamart J, De Kock M. The effect of clonidine, an alpha-2 adrenergic receptor agonist, on inflammatory response and postischemic endothelium function during early reperfusion in healthy volunteers. *J Cardiovasc Pharmacol*. 2012 Dec;60(6):553-60. doi: 10.1097/FJC.0b013e31827303fa. PMID: 22987052.
- 158: Lozano O, Laloy J, Alpan L, Mejia J, Rolin S, Toussaint O, Dogné JM, Lucas S, Masereel B. Effects of SiC nanoparticles orally administered in a rat model: biodistribution, toxicity and elemental composition changes in feces and organs. *Toxicol Appl Pharmacol*. 2012 Oct 15;264(2):232-45. doi: 10.1016/j.taap.2012.08.004. Epub 2012 Aug 15. PMID: 22981607.
- 159: Neels P, van Damme P, van Ranst M, Dogné JM. Human papillomavirus vaccines: understanding the benefit-risk. *Ann Med*. 2013 May;45(3):203-5. doi: 10.3109/07853890.2012.700117. Epub 2012 Jul 3. PMID: 22758373.
- 160: Mullier F, Rahier JF, Maignen F, Cornet Y, Graux C, Chatelain C, Chatelain B, Dogne JM. A case of therapy-related myeloid neoplasm in a patient with Crohn's disease treated with azathioprine. *Acta Haematol*. 2012;128(1):1-6. doi: 10.1159/000337046. Epub 2012 May 4. PMID: 22572218.
- 161: Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. *Thromb Haemost*. 2012 May;107(5):985-97. doi: 10.1160/TH11-11-0804. Epub 2012 Mar 22. PMID: 22438031.

- 162: Lozano O, Mejia J, Tabarrant T, Masereel B, Dogné JM, Toussaint O, Lucas S. Quantification of nanoparticles in aqueous food matrices using Particle-Induced X-ray Emission. *Anal Bioanal Chem.* 2012 Jul;403(10):2835-41. doi: 10.1007/s00216-012-5895-9. Epub 2012 Mar 13. Erratum in: *Anal Bioanal Chem.* 2012 Aug;404(2):623. PMID: 22411536.
- 163: Mullier F, Daliphard S, Garand R, Dekeyser M, Cornet Y, Luquet I, Talmant P, Richebourg S, Jamar M, Dogné JM, Chatelain C, Michaux L, Chatelain B. Morphology, cytogenetics, and survival in myelodysplasia with del(20q) or ider(20q): a multicenter study. *Ann Hematol.* 2012 Feb;91(2):203-13. doi: 10.1007/s00277-011-1286-0. Epub 2011 Jul 9. PMID: 21744002.
- 164: Dubois L, Peeters S, Lieuwes NG, Geusens N, Thiry A, Wigfield S, Carta F, McIntyre A, Scozzafava A, Dogné JM, Supuran CT, Harris AL, Masereel B, Lambin P. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. *Radiother Oncol.* 2011 Jun;99(3):424-31. doi: 10.1016/j.radonc.2011.05.045. Epub 2011 Jun 14. PMID: 21676479.
- 165: Laloy J, Robert S, Marbehant C, Mullier F, Mejia J, Piret JP, Lucas S, Chatelain B, Dogné JM, Toussaint O, Masereel B, Rolin S. Validation of the calibrated thrombin generation test (cTGT) as the reference assay to evaluate the procoagulant activity of nanomaterials. *Nanotoxicology.* 2012 Mar;6(2):213-32. doi: 10.3109/17435390.2011.569096. Epub 2011 Apr 13. PMID: 21486188.
- 166: Cherdon C, Rolin S, Hanson J, Ooms A, de Leval L, Drion P, Michiels C, Pirotte B, Masereel B, Sakalihassan N, Defraigne JO, Dogné JM. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. *Prostaglandins Other Lipid Mediat.* 2011 Apr;94(3-4):124-32. doi: 10.1016/j.prostaglandins.2011.03.001. Epub 2011 Mar 21. PMID: 21397034.
- 167: Mullier F, Lainey E, Fenneteau O, Da Costa L, Schillinger F, Bailly N, Cornet Y, Chatelain C, Dogné JM, Chatelain B. Additional erythrocytic and reticulocytic parameters helpful for diagnosis of hereditary spherocytosis: results of a multicentre study. *Ann Hematol.* 2011 Jul;90(7):759-68. doi: 10.1007/s00277-010-1138-3. Epub 2010 Dec 22. PMID: 21181161.
- 168: Mullier F, Bailly N, Cornet Y, Dubuc E, Robert S, Osselaer JC, Chatelain C, Dogné JM, Chatelain B. Contribution of platelet microparticles generation assay to the diagnosis of type II heparin-induced thrombocytopenia. *Thromb Haemost.* 2010 Jun;103(6):1277-81. doi: 10.1160/TH09-10-0711. Epub 2010 Apr 13. PMID: 20390228.
- 169: Robert S, Baccelli C, Devel P, Dogné JM, Quetin-Leclercq J. Effects of leaf extracts from *Croton zambesicus* Müell. Arg. on hemostasis. *J Ethnopharmacol.* 2010 Apr 21;128(3):641-8. doi: 10.1016/j.jep.2010.02.007. Epub 2010 Feb 26. PMID: 20219668.
- 170: Decrem Y, Rath G, Blasioli V, Cauchie P, Robert S, Beaufays J, Frère JM, Feron O, Dogné JM, Dessy C, Vanhamme L, Godfroid E. Ir-CPI, a coagulation contact phase inhibitor from the tick *Ixodes ricinus*, inhibits thrombus formation without impairing hemostasis. *J Exp Med.* 2009 Oct 26;206(11):2381-95. doi: 10.1084/jem.20091007. Epub 2009 Oct 5. PMID: 19808248; PMCID: PMC2768864.
- 171: Praticò D, Dogné JM. Vascular biology of eicosanoids and atherogenesis. *Expert Rev Cardiovasc Ther.* 2009 Sep;7(9):1079-89. doi: 10.1586/erc.09.91. PMID: 19764861.
- 172: Robert S, Ghiotto J, Pirotte B, David JL, Masereel B, Pochet L, Dogné JM. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? *Pharmacol Res.* 2009 Mar;59(3):160-6. doi: 10.1016/j.phrs.2008.12.003. Epub 2008 Dec 24. PMID: 19124079.
- 173: Thiry A, Ledecq M, Cecchi A, Frederick R, Dogné JM, Supuran CT, Wouters J, Masereel B. Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. *Bioorg Med Chem.* 2009 Jan 15;17(2):553-7. doi: 10.1016/j.bmc.2008.11.071. Epub 2008 Dec 6. PMID: 19097911.
- 174: D'Ambrosio K, Vitale RM, Dogné JM, Masereel B, Innocenti A, Scozzafava A, De Simone G, Supuran CT. Carbonic anhydrase inhibitors: bio-reductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII. *J Med Chem.* 2008 Jun 12;51(11):3230-7. doi: 10.1021/jm800121c. Epub 2008 May 16. PMID: 18481843.
- 175: Thiry A, Delayen A, Goossens L, Houssin R, Ledecq M, Frankart A, Dogné JM, Wouters J, Supuran CT, Hélichart JP, Masereel B. Synthesis and biological evaluation of a new family of anti-benzylaminosulfonamides as CA IX inhibitors. *Eur J Med Chem.* 2009 Feb;44(2):511-8. doi: 10.1016/j.ejmech.2008.03.034. Epub 2008 Apr 4. PMID: 18479784.
- 176: Robert S, Bertolla C, Masereel B, Dogné JM, Pochet L. Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. *J Med Chem.* 2008 Jun 12;51(11):3077-80. doi: 10.1021/jm8002697. Epub 2008 May 7. PMID: 18459730.
- 177: Thiry A, Rolin S, Vullo D, Frankart A, Scozzafava A, Dogné JM, Wouters J, Supuran CT, Masereel B. Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. *Eur J Med Chem.* 2008 Dec;43(12):2853-60. doi: 10.1016/j.ejmech.2008.02.018. Epub 2008 Feb 29. PMID: 18406497.
- 178: Thiry A, Supuran CT, Masereel B, Dogné JM. Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. *J Med Chem.* 2008 Jun 12;51(11):3051-6. doi: 10.1021/jm701526d. Epub 2008 Mar 19. PMID: 18348513.
- 179: Dogné JM, Thiry A, Supuran CT. Carbonic anhydrase inhibition: insight into non-COX-2 pharmacological effect of some coxibs. *Curr Pharm Des.* 2008;14(7):679-84. doi: 10.2174/138161208783877938. PMID: 18336314.
- 180: Thiry A, Dogné JM, Supuran CT, Masereel B. Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity:

- drug design and mechanism of action. *Curr Pharm Des.* 2008;14(7):661-71. doi: 10.2174/138161208783877956. PMID: 18336312.
- 181: Hanson J, Dogné JM, Ghiotto J, Moray AL, Kinsella BT, Pirotte B. Design, synthesis, and SAR study of a series of N-alkyl-N'-[2-(aryloxy)-5-nitrobenzenesulfonyl]ureas and -cyanoguanidine as selective antagonists of the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor. *J Med Chem.* 2007 Aug 9;50(16):3928-36. doi: 10.1021/jm070427h. Epub 2007 Jul 14. PMID: 17630727.
- 182: Thiry A, Masereel B, Dogné JM, Supuran CT, Wouters J, Michaux C. Exploration of the binding mode of indanesulfonamides as selective inhibitors of human carbonic anhydrase type VII by targeting Lys 91. *ChemMedChem.* 2007 Sep;2(9):1273-80. doi: 10.1002/cmdc.200700057. PMID: 17607683.
- 183: Dogné JM, Thiry A, Pratico D, Masereel B, Supuran CT. Dual carbonic anhydrase--cyclooxygenase-2 inhibitors. *Curr Top Med Chem.* 2007;7(9):885-91. doi: 10.2174/156802607780636717. PMID: 17504133.
- 184: Thiry A, Dogné JM, Supuran CT, Masereel B. Carbonic anhydrase inhibitors as anticonvulsant agents. *Curr Top Med Chem.* 2007;7(9):855-64. doi: 10.2174/156802607780636726. PMID: 17504130.
- 185: Winum JY, Thiry A, Cheikh KE, Dogné JM, Montero JL, Vullo D, Scozzafava A, Masereel B, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX, and XIV with sulfonamides incorporating fructopyranose-thioureido tails. *Bioorg Med Chem Lett.* 2007 May 15;17(10):2685-91. doi: 10.1016/j.bmcl.2007.03.008. Epub 2007 Mar 12. PMID: 17376683.
- 186: Cyrus T, Yao Y, Ding T, Dogné JM, Praticò D. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. *Eur J Pharmacol.* 2007 Apr 30;561(1-3):105-11. doi: 10.1016/j.ejphar.2006.12.024. Epub 2007 Jan 19. PMID: 17306791.
- 187: Cyrus T, Yao Y, Ding T, Dogné JM, Praticò D. Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice. *Blood.* 2007 Apr 15;109(8):3291-6. doi: 10.1182/blood-2006-08-044990. Epub 2006 Dec 7. PMID: 17158227; PMCID: PMC1852239.
- 188: Lanoye L, Segers P, Tchana-Sato V, Rolin S, Dogne JM, Ghuysen A, Lambermont B, Hanson J, Desai T, Verdonck P, D'Orio V, Kolh P. Cardiovascular haemodynamics and ventriculo-arterial coupling in an acute pig model of coronary ischaemia-reperfusion. *Exp Physiol.* 2007 Jan;92(1):127-37. doi: 10.1113/expphysiol.2006.034983. Epub 2006 Oct 12. PMID: 17038482.
- 189: Michaux C, de Leval X, Julémont F, Dogné JM, Pirotte B, Durant F. Structure-based pharmacophore of COX-2 selective inhibitors and identification of original lead compounds from 3D database searching method. *Eur J Med Chem.* 2006 Dec;41(12):1446-55. doi: 10.1016/j.ejmech.2006.07.017. Epub 2006 Oct 9. PMID: 17030482.
- 190: Thiry A, Dogné JM, Masereel B, Supuran CT. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. *Trends Pharmacol Sci.* 2006 Nov;27(11):566-73. doi: 10.1016/j.tips.2006.09.002. Epub 2006 Sep 25. PMID: 16996620.
- 191: Jaspert S, Bertholet P, Piel G, Dogné JM, Delattre L, Evrard B. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. *Eur J Pharm Biopharm.* 2007 Jan;65(1):47-56. doi: 10.1016/j.ejpb.2006.07.006. Epub 2006 Jul 20. PMID: 16962749.
- 192: Lambermont B, Delanaye P, Dogné JM, Ghuysen A, Janssen N, Dubois B, Desai T, Kolh P, D'Orio V, Krzesinski JM. Large-pore membrane hemofiltration increases cytokine clearance and improves right ventricular-vascular coupling during endotoxic shock in pigs. *Artif Organs.* 2006 Jul;30(7):560-4. doi: 10.1111/j.1525-1594.2006.00260.x. PMID: 16836739.
- 193: Hanson J, Reynaud D, Qiao N, Devel P, Moray AL, Renard JF, Kelley LP, Winum JY, Montero JL, Kinsella BT, Pirotte B, Pace-Asciak CR, Dogné JM. Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta isoforms of the human thromboxane receptor. *J Med Chem.* 2006 Jun 15;49(12):3701-9. doi: 10.1021/jm060108a. PMID: 16759113.
- 194: de Leval X, Dassesse T, Dogné JM, Waltregny D, Bellahcène A, Benoit V, Pirotte B, Castronovo V. Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents. *J Pharmacol Exp Ther.* 2006 Sep;318(3):1057-67. doi: 10.1124/jpet.106.101188. Epub 2006 May 23. PMID: 16720756.
- 195: Thiry A, Ledecq M, Cecchi A, Dogné JM, Wouters J, Supuran CT, Masereel B. Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. *J Med Chem.* 2006 May 4;49(9):2743-9. doi: 10.1021/jm0600287. PMID: 16640335.
- 196: Dogné JM, Hanson J, Supuran C, Pratico D. Coxibs and cardiovascular side-effects: from light to shadow. *Curr Pharm Des.* 2006;12(8):971-5. doi: 10.2174/138161206776055949. PMID: 16533164.
- 197: Ruan KH, Dogné JM. Implications of the molecular basis of prostacyclin biosynthesis and signaling in pharmaceutical designs. *Curr Pharm Des.* 2006;12(8):925-41. doi: 10.2174/138161206776055994. PMID: 16533160.
- 198: Dogné JM, Hanson J, de Leval X, Pratico D, Pace-Asciak CR, Drion P, Pirotte B, Ruan KH. From the design to the clinical application of thromboxane modulators. *Curr Pharm Des.* 2006;12(8):903-23. doi: 10.2174/138161206776055921. PMID: 16533159.
- 199: Kolh P, Rolin S, Tchana-Sato V, Péteïn M, Ghuysen A, Lambermont B, Hanson J, Magis D, Segers P, Masereel B, D'Orio V, Dogne JM. Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of

- myocardial ischemia-reperfusion. Prostaglandins Other Lipid Mediat. 2006 Mar;79(1-2):53-73. doi: 10.1016/j.prostaglandins.2005.10.002. Epub 2005 Dec 22. PMID: 16516810.
- 200: Rolin S, Masereel B, Dogné JM. Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol. 2006 Mar 8;533(1-3):89-100. doi: 10.1016/j.ejphar.2005.12.058. Epub 2006 Feb 3. PMID: 16458293.
- 201: Tchana-Sato V, Dogné JM, Lambermont B, Ghuysen A, Magis D, Morimont P, Hanson J, D'Orio V, Limet R, Kolh P. Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig. Prostaglandins Other Lipid Mediat. 2005 Dec;78(1-4):82-95. doi: 10.1016/j.prostaglandins.2005.04.001. Epub 2005 Jun 20. PMID: 16303607.
- 202: Dogné JM, Hanson J, Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci. 2005 Dec;26(12):639-44. doi: 10.1016/j.tips.2005.10.001. Epub 2005 Oct 21. PMID: 16243403.
- 203: Michaux C, Charlier C, Julémont F, de Leval X, Dogné JM, Pirotte B, Durant F. A new potential cyclooxygenase-2 inhibitor, pyridinic analogue of nimesulide. Eur J Med Chem. 2005 Dec;40(12):1316-24. doi: 10.1016/j.ejmech.2005.08.003. Epub 2005 Oct 11. PMID: 16225966.
- 204: Dogné JM, Rolin S, Péteïn M, Tchana-Sato V, Ghuysen A, Lambermont B, Hanson J, Magis D, Segers P, Pirotte B, Masereel B, Drion P, D'Orio V, Kolh P. Characterization of an original model of myocardial infarction provoked by coronary artery thrombosis induced by ferric chloride in pig. Thromb Res. 2005;116(5):431-42. doi: 10.1016/j.thromres.2005.02.006. Epub 2005 Mar 23. PMID: 16122556.
- 205: Praticò D, Dogné JM. Selective cyclooxygenase-2 inhibitors development in cardiovascular medicine. Circulation. 2005 Aug 16;112(7):1073-9. doi: 10.1161/CIRCULATIONAHA.104.524231. PMID: 16103258.
- 206: Ghuysen A, Dogné JM, Chiap P, Rolin S, Masereel B, Lambermont B, Kolh P, Tchana-Sato V, Hanson J, D'Orio V. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor. Cardiovasc Drug Rev. 2005 Spring;23(1):1-14. doi: 10.1111/j.1527-3466.2005.tb00153.x. PMID: 15867944.
- 207: Dogné JM, Supuran CT, Pratico D. Adverse cardiovascular effects of the coxibs. J Med Chem. 2005 Apr 7;48(7):2251-7. doi: 10.1021/jm0402059. PMID: 15801815.
- 208: Winum JY, Dogné JM, Casini A, de Leval X, Montero JL, Scozzafava A, Vullo D, Innocenti A, Supuran CT. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties. J Med Chem. 2005 Mar 24;48(6):2121-5. doi: 10.1021/jm0494826. PMID: 15771455.
- 209: Kolh P, Lambermont B, Ghuysen A, Tchana-Sato V, Dogné JM, Hanson J, Gerard P, D'Orio V, Pierard L, Limet R. Effects of dobutamine on left ventriculoarterial coupling and mechanical efficiency in acutely ischemic pigs. J Cardiovasc Pharmacol. 2005 Feb;45(2):144-52. doi: 10.1097/01.fjc.0000151928.27273.02. PMID: 15654263.
- 210: Hanson J, Rolin S, Reynaud D, Qiao N, Kelley LP, Reid HM, Valentin F, Tippins J, Kinsella BT, Masereel B, Pace-Asciak C, Pirotte B, Dogné JM. In vitro and in vivo pharmacological characterization of BM-613 [N-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist. J Pharmacol Exp Ther. 2005 Apr;313(1):293-301. doi: 10.1124/jpet.104.079301. Epub 2004 Dec 30. PMID: 15626721.
- 211: Julémont F, de Leval X, Michaux C, Renard JF, Winum JY, Montero JL, Damas J, Dogné JM, Pirotte B. Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. J Med Chem. 2004 Dec 30;47(27):6749-59. doi: 10.1021/jm0494801. PMID: 15615524.
- 212: Mouithys-Mickalad A, Deby-Dupont G, Dogné JM, de Leval X, Kohlen S, Navet R, Sluse F, Hoebeker M, Pirotte B, Lamy M. Effects of COX-2 inhibitors on ROS produced by Chlamydia pneumoniae-primed human promonocytic cells (THP-1). Biochem Biophys Res Commun. 2004 Dec 24;325(4):1122-30. doi: 10.1016/j.bbrc.2004.10.155. PMID: 15555544.
- 213: Kolh P, Lambermont B, Ghuysen A, Tchana-Sato V, Dogné JM, D'Orio V, Gerard P, Larbuisson R, Limet R. Comparison of the effects of propofol and pentobarbital on left ventricular adaptation to an increased afterload. J Cardiovasc Pharmacol. 2004 Sep;44(3):294-301. doi: 10.1097/01.fjc.0000133050.11105.c2. PMID: 15475825.
- 214: Lambermont B, Segers P, Ghuysen A, Tchana-Sato V, Morimont P, Dogné JM, Kolh P, Gerard P, D'Orio V. Comparison between single-beat and multiple-beat methods for estimation of right ventricular contractility. Crit Care Med. 2004 Sep;32(9):1886-90. doi: 10.1097/01.ccm.0000139607.38497.8a. PMID: 15343017.
- 215: Hanson J, de Leval X, David JL, Supuran C, Pirotte B, Dogné JM. Progress in the field of GPIIb/IIIa antagonists. Curr Med Chem Cardiovasc Hematol Agents. 2004 Apr;2(2):157-67. doi: 10.2174/1568016043477224. PMID: 15320798.
- 216: Roland I, De Leval X, Evrard B, Pirotte B, Dogné JM, Delattre L. Modulation of the arachidonic cascade with omega3 fatty acids or analogues: potential therapeutic benefits. Mini Rev Med Chem. 2004 Aug;4(6):659-68. doi: 10.2174/1389557043403738. PMID: 15279600.
- 217: Dogné JM, Hanson J, de Leval X, Masereel B, Kolh P, Pirotte B. New developments on thromboxane modulators. Mini Rev Med Chem. 2004 Aug;4(6):649-57. doi: 10.2174/1389557043403684. PMID: 15279599.
- 218: Julémont F, Dogné JM, Pirotte B, de Leval X. Recent development in the

field of dual COX / 5-LOX inhibitors. *Mini Rev Med Chem.* 2004 Aug;4(6):633-8. doi: 10.2174/1389557043403747. PMID: 15279597.

219: de Leval X, Julémont F, Benoit V, Frederich M, Pirotte B, Dogné JM. First and second generations of COX-2 selective inhibitors. *Mini Rev Med Chem.* 2004 Aug;4(6):597-601. doi: 10.2174/1389557043403693. PMID: 15279593.

220: de Leval X, Iliés M, Casini A, Dogné JM, Scozzafava A, Masini E, Mincione F, Starnotti M, Supuran CT. Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity. *J Med Chem.* 2004 May 20;47(11):2796-804. doi: 10.1021/jm031116j. PMID: 15139757.

221: de Leval X, Hanson J, David JL, Masereel B, Pirotte B, Dogné JM. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. *Curr Med Chem.* 2004 May;11(10):1243-52. doi: 10.2174/0929867043365279. PMID: 15134517.

222: Dogné JM, de Leval X, Hanson J, Frederich M, Lambermont B, Ghuysen A, Casini A, Masereel B, Ruan KH, Pirotte B, Kolh P. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. *Curr Med Chem.* 2004 May;11(10):1223-41. doi: 10.2174/0929867043365260. PMID: 15134516.

223: Ghuysen A, Lambermont B, Dogné JM, Kolh P, Tchana-Sato V, Morimont P, Magis D, Hanson J, Segers P, D'Orio V. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism. *J Pharmacol Exp Ther.* 2004 Sep;310(3):964-72. doi: 10.1124/jpet.104.066852. Epub 2004 Apr 30. PMID: 15121765.

224: Dogné JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, Rolin S, Ghuysen A, Segers P, Lambermont B, Masereel B, Pirotte B. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. *J Pharmacol Exp Ther.* 2004 May;309(2):498-505. doi: 10.1124/jpet.103.063610. Epub 2004 Jan 23. PMID: 14742735.

225: Dogné JM, de Leval X, Benoit P, Delarge J, Masereel B. Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. *Am J Respir Med.* 2002;1(1):11-7. doi: 10.1007/BF03257158. PMID: 14720071.

226: Lambermont B, Kolh P, Ghuysen A, Segers P, Dogné JM, Tchana-Sato V, Morimont P, Benoit P, Gérard P, Masereel B, D'Orio V. Effect of a novel thromboxane A2 inhibitor on right ventricular-arterial coupling in endotoxic shock. *Shock.* 2004 Jan;21(1):45-51. doi: 10.1097/01.shk.0000095935.86703.ca. PMID: 14676683.

227: Michaux C, Dogné JM, Rolin S, Masereel B, Wouters J, Durant F. A pharmacophore model for sulphonyl-urea (-cyanoguanidine) compounds with dual action, thromboxane receptor antagonists and thromboxane synthase inhibitors. *Eur J Med Chem.* 2003 Jul-Aug;38(7-8):703-10. doi: 10.1016/s0223-5234(03)00076-x. PMID: 12932901.

228: Lambermont B, Ghuysen A, Kolh P, Tchana-Sato V, Segers P, Gérard P, Morimont P, Magis D, Dogné JM, Masereel B, D'Orio V. Effects of endotoxic shock on right ventricular systolic function and mechanical efficiency. *Cardiovasc Res.* 2003 Aug 1;59(2):412-8. doi: 10.1016/s0008-6363(03)00368-7. PMID: 12909324.

229: Segers P, Tchana-Sato V, Leather HA, Lambermont B, Ghuysen A, Dogné JM, Benoit P, Morimont P, Wouters PF, Verdonck P, Kolh P. Determinants of left ventricular preload-adjusted maximal power. *Am J Physiol Heart Circ Physiol.* 2003 Jun;284(6):H2295-301. doi: 10.1152/ajpheart.01110.2002. Epub 2003 Mar 13. PMID: 12637350.

230: Benoit P, Dogné JM. Platelet ADP receptors and their antagonists. *Mini Rev Med Chem.* 2003 Mar;3(2):145-8. doi: 10.2174/1389557033405412. PMID: 12570847.

231: Julémont F, de Leval X, Michaux C, Damas J, Charlier C, Durant F, Pirotte B, Dogné JM. Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors. *J Med Chem.* 2002 Nov 7;45(23):5182-5. doi: 10.1021/jm020920n. PMID: 12408728.

232: Michaux C, Dogné JM, Norberg B, Durant F, Masereel B. N-tert-butyl-N'-(2-cyclohexylamino-5-nitrobenzenesulfonyl)urea, BM531, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition. *Acta Crystallogr C.* 2002 Oct;58(Pt 10):o621-3. doi: 10.1107/s0108270102016463. Epub 2002 Sep 30. PMID: 12359948.

233: Frédéricich M, Dogné JM, Angenot L, De Mol P. New trends in anti-malarial agents. *Curr Med Chem.* 2002 Aug;9(15):1435-56. doi: 10.2174/0929867023369691. PMID: 12173975.

234: Leval Xd, Julemont F, Delarge J, Pirotte B, Dogne JM. New trends in dual 5-LOX/COX inhibition. *Curr Med Chem.* 2002 May;9(9):941-62. doi: 10.2174/0929867024606713. PMID: 11966455.

235: Dogne JM, de Leval X, Benoit P, Delarge J, Masereel B, David JL. Recent advances in antiplatelet agents. *Curr Med Chem.* 2002 Mar;9(5):577-89. doi: 10.2174/0929867024606948. PMID: 11945125.

236: Dogné JM, de Leval X, Benoit P, Rolin S, Pirotte B, Masereel B. Therapeutic potential of thromboxane inhibitors in asthma. *Expert Opin Investig Drugs.* 2002 Feb;11(2):275-81. doi: 10.1517/13543784.11.2.275. PMID: 11829716.

237: Michaux C, Charlier C, Julémont F, Dogné JM, de Leval X, Norberg B, Pirotte B, Durant F. N-(3-Phenoxy-4-pyridinio)methanesulfonamide. *Acta Crystallogr C.* 2002 Feb;58(Pt 2):o88-9. doi: 10.1107/s0108270101018595. Epub 2002 Jan 23. PMID: 11828118.

**Projects** Involved in academic research in pharmacovigilance, drug safety and clinical pharmacology.

**Memberships** Member of the Académie royale de Médecine de Belgique.  
Member of the federal public service health, food chain safety and environment

**Other Relevant Information**